skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SU-F-P-55: Testicular Scatter Dose Determination During Prostate SBRT with and Without Pelvic Lymph Nodes

Abstract

Purpose: The elective irradiation of pelvis lymph node for prostate cancer is still controversial. Including pelvic lymph node as part of the planning target volume could increase the testicular scatter dose, which could have a clinical impact. The objective of this work was to measure testicular scatter dose for prostate SBRT treatment with and without pelvic lymph nodes using TLD dosimetry. Methods: A 6MV beam (1000UM/min) produce by a Novalis TX (BrainLAB-VARIAN) equipped HDMLC was used. Treatment plan were done using iPlan v4.5.3 (BrainLAB) treatment planning system with sliding windows IMRT technique. Prostate SBRT plan (PLAN-1) uses 9 beams with a dose prescription (D95%) of 4000cGy in 5 fractions. Prostate with lymph nodes SBRT plan (PLAN-2) uses 11 beams with a dose prescription (D95%) of 4000cGy to the prostate and 2500cGy to the lymph node in 5 fractions. An anthropomorphic pelvic phantom with a testicular volume was used. Phantom was positioned using ExacTrac IGRT system. Phosphor TLDs LiF:Mg, Ti (TLD700 Harshaw) were positioned in the anterior, posterior and inferior portion of the testicle. Two set of TLD measurements was done for each treatment plan. TLD in vivo dosimetry was done in one patient for each treatment plan. Results: The averagemore » phantom scatter doses per fraction for the PLAN-1 were 10.9±1cGy (anterior), 7.8±1cGy (inferior) and 10.7±1cGy (posterior) which represent an average total dose of 48±1cGy (1.2% of prostate dose prescription). The doses for PLAN-2 plan were 17.7±1cGy (anterior), 11±1cGy (inferior) and 13.3±1cGy (posterior) which represent an average total dose of 70.1±1cGy (1.8% of prostate dose prescription). The average dose for in vivo patient dosimetry was 60±1cGy for PLAN-1 and 85±1cGy for PLAN-2. Conclusion: Phantom and in vivo dosimetry shows that the pelvic lymph node irradiation with SBRT slightly increases the testicular scatter dose, which could have a clinical impact.« less

Authors:
; ; ; ;  [1];  [2]
  1. Instituto de Radioterapia - Fundacion Marie Curie, Cordoba (Argentina)
  2. Ceprocor, Cordoba (Argentina)
Publication Date:
OSTI Identifier:
22626725
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Physics; Journal Volume: 43; Journal Issue: 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 61 RADIATION PROTECTION AND DOSIMETRY; BEAMS; IN VIVO; IRRADIATION; LYMPH; LYMPH NODES; NEOPLASMS; PATIENTS; PELVIS; PHANTOMS; PLANNING; PROSTATE; RADIATION DOSES; RADIOTHERAPY; TESTES; THERMOLUMINESCENT DOSIMETRY

Citation Formats

Venencia, C, Garrigo, E, Castro Pena, P, Torres, J, Zunino, S, and Germanier, A. SU-F-P-55: Testicular Scatter Dose Determination During Prostate SBRT with and Without Pelvic Lymph Nodes. United States: N. p., 2016. Web. doi:10.1118/1.4955762.
Venencia, C, Garrigo, E, Castro Pena, P, Torres, J, Zunino, S, & Germanier, A. SU-F-P-55: Testicular Scatter Dose Determination During Prostate SBRT with and Without Pelvic Lymph Nodes. United States. doi:10.1118/1.4955762.
Venencia, C, Garrigo, E, Castro Pena, P, Torres, J, Zunino, S, and Germanier, A. Wed . "SU-F-P-55: Testicular Scatter Dose Determination During Prostate SBRT with and Without Pelvic Lymph Nodes". United States. doi:10.1118/1.4955762.
@article{osti_22626725,
title = {SU-F-P-55: Testicular Scatter Dose Determination During Prostate SBRT with and Without Pelvic Lymph Nodes},
author = {Venencia, C and Garrigo, E and Castro Pena, P and Torres, J and Zunino, S and Germanier, A},
abstractNote = {Purpose: The elective irradiation of pelvis lymph node for prostate cancer is still controversial. Including pelvic lymph node as part of the planning target volume could increase the testicular scatter dose, which could have a clinical impact. The objective of this work was to measure testicular scatter dose for prostate SBRT treatment with and without pelvic lymph nodes using TLD dosimetry. Methods: A 6MV beam (1000UM/min) produce by a Novalis TX (BrainLAB-VARIAN) equipped HDMLC was used. Treatment plan were done using iPlan v4.5.3 (BrainLAB) treatment planning system with sliding windows IMRT technique. Prostate SBRT plan (PLAN-1) uses 9 beams with a dose prescription (D95%) of 4000cGy in 5 fractions. Prostate with lymph nodes SBRT plan (PLAN-2) uses 11 beams with a dose prescription (D95%) of 4000cGy to the prostate and 2500cGy to the lymph node in 5 fractions. An anthropomorphic pelvic phantom with a testicular volume was used. Phantom was positioned using ExacTrac IGRT system. Phosphor TLDs LiF:Mg, Ti (TLD700 Harshaw) were positioned in the anterior, posterior and inferior portion of the testicle. Two set of TLD measurements was done for each treatment plan. TLD in vivo dosimetry was done in one patient for each treatment plan. Results: The average phantom scatter doses per fraction for the PLAN-1 were 10.9±1cGy (anterior), 7.8±1cGy (inferior) and 10.7±1cGy (posterior) which represent an average total dose of 48±1cGy (1.2% of prostate dose prescription). The doses for PLAN-2 plan were 17.7±1cGy (anterior), 11±1cGy (inferior) and 13.3±1cGy (posterior) which represent an average total dose of 70.1±1cGy (1.8% of prostate dose prescription). The average dose for in vivo patient dosimetry was 60±1cGy for PLAN-1 and 85±1cGy for PLAN-2. Conclusion: Phantom and in vivo dosimetry shows that the pelvic lymph node irradiation with SBRT slightly increases the testicular scatter dose, which could have a clinical impact.},
doi = {10.1118/1.4955762},
journal = {Medical Physics},
number = 6,
volume = 43,
place = {United States},
year = {Wed Jun 15 00:00:00 EDT 2016},
month = {Wed Jun 15 00:00:00 EDT 2016}
}